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Blockade of TGF-β signaling to enhance 
the antitumor response is accompanied 
by dysregulation of the functional activity 
of  CD4+CD25+Foxp3+ and  CD4+CD25−Foxp3+ 
T cells
Magdalena J. Polanczyk1, Edwin Walker1,2, Daniel Haley1, Bella S. Guerrouahen3* and Emmanuel T. Akporiaye1,2*
Abstract 
Background: The pleiotropic cytokine, transforming growth factor (TGF)-β, and  CD4+CD25+Foxp3+ regulatory T 
cells (Tregs) play a critical role in actively suppressing antitumor immune responses. Evidence shows that TGF-β pro-
duced by tumor cells promotes tolerance via expansion of Tregs. Our group previously demonstrated that blockade 
of TGF-β signaling with a small molecule TGF-β receptor I antagonist (SM16) inhibited primary and metastatic tumor 
growth in a T cell dependent fashion. In the current study, we evaluated the effect of SM16 on Treg generation and 
function.
Methods: Using BALB/c, FoxP3eGFP and  Rag−/− mice, we performed FACS analysis to determine if SM16 blocked 
de novo TGF-β-induced Treg generation in vitro and in vivo.  CD4+ T cells from lymph node and spleen were isolated 
from control mice or mice maintained on SM16 diet, and flow cytometry analysis was used to detect the frequency of 
 CD4+CD25−FoxP3+ and  CD4+CD25+FoxP3+ T cells. In vitro suppression assays were used to determine the ability to 
suppress naive T cell proliferation in vitro of both  CD4+CD25+FoxP3+ and  CD4+CD25−FoxP3+ T cell sub-populations. 
We then examined whether SM16 diet exerted an inhibitory effect on primary tumor growth and correlated with 
changes in  FoxP3+expression. ELISA analysis was used to measure IFN-γ levels after 72 h co-culture of  CD4+CD25+ T 
cells from tumor-bearing mice on control or SM16 diet with  CD4+CD25− T cells from naive donors.
Results: SM16 abrogates TGF-β-induced Treg generation in vitro but does not prevent global homeostatic 
expansion of  CD4+ T cell sub-populations in vivo. Instead, SM16 treatment causes expansion of a population of 
 CD4+CD25−Foxp3+ Treg-like cells without significantly altering the overall frequency of Treg in lymphoreplete naive 
and tumor-bearing mice. Importantly, both the  CD4+CD25−Foxp3+ T cells and the  CD4+CD25+Foxp3+ Tregs in mice 
receiving SM16 diet exhibited diminished ability to suppress naive T cell proliferation in vitro compared to Treg from 
mice on control diet.
Conclusions: These findings suggest that blockade of TGF-β signaling is a potentially useful strategy for blunting 
Treg function to enhance the anti-tumor response. Our data further suggest that the overall dampening of Treg func-
tion may involve the expansion of a quiescent Treg precursor population, which is  CD4+CD25−Foxp3+.
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Background
Compelling evidence gathered in recent years indicates 
that transforming growth factor β (TGF-β) plays a central 
role in promoting tumor growth, metastasis and invasive-
ness [1–4]. Due to the broad range of its biological activ-
ity, TGF-β acts as both a growth factor for tumor cells 
[5–7] and a suppressor of immune cell function [8–11]. 
Emerging evidence indicates that TGF-β produced by 
tumor cells promotes immunological tolerance [12, 13] 
via expansion of T regulatory cells (Tregs). The increased 
frequency of Treg in patients with cancer can be inversely 
correlated with survival [14–20]. TGF-β is known as one 
of the key factors responsible for the development and 
homeostasis of tolerance [2, 21–25]. Thus, it has become 
apparent that elevated levels of TGF-β in cancer patients 
and tumor bearing mice may enhance immune tolerance 
to tumors by expanding the regulatory T cell compart-
ment and directly inhibiting effector cell mechanisms 
from clearing the established tumor. This leads to tumor 
evasion and ineffectiveness of immune-based clinical 
approaches to boost host immunity.
In our previous studies, we demonstrated that block-
ade of TGF-β signaling using a small molecule TGF-β 
receptor I antagonist (SM16) inhibited primary and 
metastatic tumor growth in a T cell dependent fashion 
[19, 26]. In the current study, we evaluated the effect of 
SM16 on Treg generation and function. We demonstrate 
that SM16 abrogates TGF-β-induced Treg generation 
in vitro but does not prevent global homeostatic expan-
sion of  CD4+ T cell subpopulations in  vivo. Instead, 
SM16 treatment causes expansion of a population of 
 CD4+CD25−Foxp3+ Treg-like cells without significantly 
altering the overall frequency of Treg in lymphoreplete 
naive and tumor-bearing mice. Importantly, both the 
 CD4+CD25−Foxp3+ and the  CD4+CD25+Foxp3+ T cells 
in mice receiving SM16 diet exhibited diminished abil-
ity to suppress naive T cell proliferation in an in  vitro 
assay compared to Treg from mice on control diet. These 
findings suggest that blockade of TGF-β signaling is a 
potentially useful strategy for eliminating Treg function 
to enhance the anti-tumor response. Our data further 
suggest that the overall dampening of Treg function may 
involve the expansion of a quiescent Treg precursor pop-
ulation, which is  CD4+CD25−Foxp3+.
Methods
Reagents
Fluorescein isothiocyanate (FITC), Allophycocyanin cya-
nine tandem (APC-H7), R-phycoerythrin (PE) or Allo-
phycocyanin (APC)-conjugated monoclonal antibodies 
(mAbs) were used for cytofluorometric analysis of anti-
mouse Ki67 (BD PharMingen, San Diego, CA, USA), anti-
mouse CD4, anti-mouse CD25 and anti-mouse FoxP3 
(eBioscience, San Diego, CA). Purified hamster anti-
mouse mAbs, anti-CD3 (clone 145-2C11) and anti-CD28 
(clone 37.51) were also purchased from BD Pharmingen. 
Recombinant TGF-β was purchased from Peprotech (NJ, 
USA). TGF-β neutralizing mAb (1D11) was a gift from 
Dr. Hong-Ming Hu (Earle A. Chiles Research Institute, 
Portland, OR). Cell enrichment kits for  CD4+ and Anti-
gen Presenting Cells (APC, CD90.1−) were purchased 
from MACS Miltenyi Biotec Inc., (Auburn, CA, USA). 
Dead Fixable Violet Dead Cell Stain Kit was purchased 
from Invitrogen (L34955, Carlsbad, CA).
Sm16
SM16 is a novel, orally bioavailable kinase inhibitor that 
binds to the ATP-binding pocket of TGF-βR1 (ALK5), 
inhibiting its activation [19, 27, 28]. When tested against 
a panel of 35 unrelated kinases, SM16 was shown to be 
highly selective for ALK5 and only moderately inhibited 
the activity of p38α and Raf [29]. SM16 was kindly pro-
vided by Biogen Idec (Cambridge, MA, USA) under a 
Materials Transfer Agreement. For in vitro studies, SM16 
was reconstituted in dimethyl sulfoxide (DMSO) and 
used at a final concentration of 10 µM. For the oral treat-
ment studies, mice were put on mouse chow containing 
SM16 (0.45 g SM16/kg food) (Research Diets, New Brun-
swick, NJ, USA). Control mice were kept on nutrient-
matched AIN93G diet.
Mice
Six to eight weeks old female BALB/c, C57BL/6,  Rag−/− 
knockout mice were purchased from the Jackson Labora-
tory (Bar Harbor, ME). B6.Cg-FoxP3tm2Tch/J (FoxP3eGFP) 
were bred in the Animal Facility at the Earle A. Chiles 
Research Institute (EACRI), Portland, OR. All mice were 
housed at the EACRI Animal Care Facility in accordance 
with the Principles of Animal Care (NIH publication no. 
85-23, revised 1985). The Institutional Animal Care and 
Use Committee (IACUC) of the EACRI approved all pro-
tocols in compliance with the Guide for the Care and Use 
of Laboratory Animals. All mice were maintained under 
specific pathogen-free conditions, fed food and water 
ad  libitum. Mice were routinely checked for any abnor-
malities until the experiment was terminated. Euthana-
sia was performed according to guidelines for carbon 
dioxide asphyxiation when tumor burden was excessive 
or when mice progressed to a moribund state. No unex-
pected deaths occurred during this study.
Tumor cell line and tumor induction
The 4T1 tumor cell line is a poorly immunogenic, highly 
metastatic variant of 410.4, a tumor subline isolated 
from a spontaneous mammary tumor that developed in 
a BALB/cfC3H mouse [30]. The 4T1 tumor was chosen 
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because it is an aggressive TGF-beta-secreting tumor 
[31] that bears a resemblance to human breast cancer [32, 
33]. It was originally kindly provided by Dr. Fred Miller 
of the Michigan Cancer Foundation (Detroit, MI, USA). 
The cells were maintained for a limited time in vitro by 
passage in complete Dulbecco’s modified Eagle’s medium 
(cDMEM; Lonza, Walkersville, MD, USA), containing 
100 U/mL penicillin, 100 mg/mL streptomycin (HyClone 
Laboratories, Logan, UT, USA), 0.025  mg/mL ampho-
tericin B (HyClone Laboratories) and 10% fetal bovine 
serum (FBS; Lonza). Trypsin-versene mixture was pur-
chased from (BioWhittaker, MD, USA). For tumor induc-
tion, cells were detached using trypsin-versene mixture 
by incubation for 5 min at 37 °C. Subsequently, cells were 
harvested, counted, spun and adjusted to a concentration 
of 1 × 106 cells/mL. For tumor induction, 5 × 104 cells (in 
50  µL volume) were injected subcutaneously (s.c.) into 
the mammary fat pad. When tumors became palpable, 
mice were randomized to different groups prior to start 
of treatment.
Isolation of spleen, lymph node and tumor‑infiltrating 
lymphocytes
Tumor draining inguinal lymph nodes (TDLN) and 
spleens were resected and pushed through a 70 μm nylon 
sieve (BD Biosciences Discovery Labware, Two Oaks, 
CA) to produce a single cell suspension. The cells were 
then washed (300×g, 7 min) and filtered through a 40 μm 
nylon sieve (BD Biosciences). After red blood cell lysis, 
the cells were washed (300×g, 7 min) and filtered through 
a 40 μm nylon sieve. To isolate tumor infiltrating immune 
cells, tumors were resected and minced using a scalpel 
blade in triple enzyme digest mix containing 10 mg/mL 
collagenase type IV (Worthington 8 Biochemical Corp. 
Lakewood, NJ), 1 mg/mL hyaluronidase (Sigma-Aldrich, 
St Louis, MO), 200 μg/mL DNAse I (Roche Applied Sci-
ences, Indianapolis, IN) in Hank’s balanced salt solution 
(HBSS, Lonza). The tumors were then incubated with 
agitation (37  °C, 45  min). After addition of ethylenedi-
aminetetraacetic acid (EDTA, 10  mM), the digest was 
incubated for another 15 min. Subsequently, the digested 
tissue was pushed sequentially through 70 μm and 40 μm 
nylon sieves, washed (300×g, 7  min), overlaid on Ficoll 
(FicoLite-LM, Atlanta Biologicals, Lawrenceville, GA) 
and centrifuged (1500×g, 25  min, without brake). The 
interface was collected and washed twice (300×g, 7 min).
Cell enrichment
For purification of  CD4+ T cells, single cell suspensions 
of splenocytes were enriched untouched by immunomag-
netic bead selection using MACS Miltenyi system (Milte-
nyi, Auburn, CA, USA) according to the manufacturer’s 
protocol Briefly,  CD4+ T cells were enriched by depletion 
of magnetically labeled contaminating CD8α+,  CD11b+, 
 CD11c+,  CD19+, CD45R (B220)+, CD49b (DX5)+, 
 CD105+, MHC-class  II+, and Ter-119+ (erythroid) cells. 
The highly enriched (90%)  CD4+ T cells were subse-
quently stained with anti-CD4 and anti-CD25 mAbs, 
and, depending on the cell donor, either  CD4+CD25+ 
cells (BALB/c), or  CD4+CD25+FoxP3+ (FoxP3eGFP) cells 
were sorted from  CD4+CD25– or  CD4+CD25–FoxP3− 
cells respectively, using a FACSAria sorter (BD Immuno-
cytometry Systems, San Jose, CA). In some experiments, 
 CD4+CD25–FoxP3+ cells were also enriched. Naive mice 
served as donors of responder T cells  (CD4+CD25– or 
 CD4+CD25–GFP–) and  CD4+ enrichment was done as 
described above. In addition, splenocytes from naive 
female mice were also used to prepare APC. Briefly, cells 
were incubated on ice for 15 min with anti-CD90.1 PE-
conjugated microbeads. After wash, cells were sorted 
using the MACS magnetic column. The negative fraction 
(CD90.1−) was washed, re-suspended at 1 × 106/mL in 
cRPMI and irradiated with 30 Gy in a cesium irradiator. 
The overall purity of T cell-depleted APC was ~ 80%.
Generation of induced Treg in vitro
For the in vitro induction of Treg cells, 6-well plates were 
coated with anti-CD3 and anti-CD28 mAbs 24 h prior to 
the assay in PBS at 4  °C. Two different concentration of 
Abs were used to induce the activation of naive T cells 
and they were respectively: 2 µg of CD3/CD28 per mL or 
10  µg of CD3 and 3  µg of CD28 per mL. Subsequently, 
plates were rinsed 3 times with fresh PBS and 1 × 106 
FACSAria enriched  CD4+CD25– or  CD4+CD25–GFP– 
T cells were seeded in the plate in the presence of 2 ng/
mL of recombinant TGF-β for 72 h in cRPMI. The TGF-β 
neutralizing Ab (1D11) or SM16 was added to some cul-
tures. After 72 h, cells were harvested and washed once 
in cRPMI. The cell pellet was reconstituted in 0.2 mL of 
cold PBS and FoxP3 expression was determined after 
antibody staining.
Adoptive T cell transfer
For adoptive transfer, MACS-enriched  CD4+ spleen 
cells from FoxP3eGFP donors were sorted into 
 CD4+CD25–GFP– and  CD4+CD25+GFP+ populations. 
An average of 5 × 106  CD4+CD25–GFP–cells were trans-
ferred i.v. into each  Rag−/− recipient. Upon injection, 
mice were separated into two groups and maintained 
either on vehicle or SM16 diet for up to 21 days.
Flow cytometry
Five-color (FITC, PE, APC, APC-H7, PB) flow cytom-
etry analysis of stained cells was performed to deter-
mine  FoxP3+ cell frequency, as well as the phenotype and 
proliferation of cells isolated from lymph node, spleen 
Page 4 of 12Polanczyk et al. J Transl Med          (2019) 17:219 
and tumor in untreated and SM16-treated mice. Briefly, 
pooled cells were divided equally (1 × 106 cells per tube) 
and washed with PBS and pre-incubated for 30  min at 
4  °C with 1  µL of live/dead cell stain kit. Subsequently, 
cells were washed twice in staining buffer, and cells iso-
lated from tumors were pre-incubated additionally with 
anti-mouse CD16/CD32 (FcBlock, BDPharMingen) 
mAb to block non-specific binding to Fc receptors and 
extracellular staining for CD4, CD25 was performed for 
25 min on ice. After incubation, cells were washed three 
times with staining medium and intracellular staining for 
FoxP3 and Ki67 was performed using a modified eBio-
science protocol. Briefly, cells were fixed for 45 min and 
washed twice with 2 mL of eBioscience permeabilization 
buffer. The cells were stained for 15  min with Fc-Block 
followed 10 min later with fluorescent-labeled antibodies 
to Ki67, FoxP3 or proper isotype control. The cells were 
then washed twice with 2 mL of permeabilization buffer, 
re-suspended in staining buffer and run on an LSRII Flow 
cytometer. Data were analyzed on FlowJo software (Tree-
Star, Inc., Ashland, OR, USA). Data represent 10,000 
gated  CD4+ T cells unless otherwise noted.
Treg suppression assay
After FACSAria sort of MACS-purified  CD4+ T cells, 
the enriched negative fraction of either  CD4+CD25– or 
 CD4+CD25–GFP– was washed, re-suspended at 1 × 106/
mL in cRPMI. The CD90-depleted irradiated spleno-
cytes of naive mice served as source of APCs. For in vitro 
assays, cells were re-suspended in complete Roswell Park 
Memorial Institute 1640 medium (cRPMI 1640) con-
taining 100 U/mL penicillin, 100  mg/mL streptomycin 
(HyClone Laboratories), 0.025  mg/mL amphotericin B 
(HyClone Laboratories), 70  μM β-2-mercaptoethanol 
(Sigma-Aldrich), 2  mM  l-glutamine (Lonza), 1  mM 
sodium pyruvate (Lonza), 1 × nonessential amino 
acids (Lonza), 10  mM HEPES (4-(2-hydroxyethyl)-
1-piperazineethanesulfonic acid; Lonza) and 10% FBS 
(Lonza). Suppression assays were performed in 96-well 
round-bottomed plates (Becton–Dickinson) in a final 
volume of 200  µL per well of cRPMI. Both APC and 
responder cells  (CD4+CD25– or  CD4+CD25–  FoxP3–) 
were plated at 0.5 ×  104 cells per well in triplicates and 
suppressor cells  (CD4+CD25+,  CD4+CD25+FoxP3+ 
or  CD4+CD25–FoxP3+) were added at the following 
responder to Treg ratios: 1:0, 1:1, 1:0.5, 1:0.25, 1:0.1 and 
0:1. Anti-CD3 antibody was added to each co-culture at 
a final concentration of 1  µg per mL. Co-cultures were 
incubated for 48 h and  [3H]-thymidine was added during 
the last 12–18 h of culture. Subsequently, the cells were 
harvested on glass fiber filters and assessed for uptake of 
the labeled thymidine by liquid scintillation counting.
IFN‑γ ELISA
For in  vitro assay of IFN-γ secretion, co-cultures of 
suppressors and responders were plated at 1:1 ratio in 
a 48-well plate. Wells containing only suppressor or 
responder cells were included as controls. Cell-free 
supernatants were harvested after 72  h and stored fro-
zen at − 20  °C until the cytokine assay was performed. 
The amount of IFN-γ was evaluated in triplicate using 
the OptEIA ELISA kit (Pharmingen). A standard curve 
was generated to evaluate concentrations of IFN-γ in 
the samples using GraphPad Prism version 5b software 
(GraphPad Software, La Jolla, CA, USA).
Statistical analysis
Statistical significance of differences among data sets 
of treatment groups was assessed by Student’s t-test for 
pair-wise comparisons or for comparisons of multiple 
groups by one-way analysis of variances (ANOVA) with 
Tukey’s HSD test to adjust for multiple comparisons. All 
analyses were performed using Prism software (Graph-
Pad, San Diego, CA). Probability values (P) of < 0.05 were 
considered indicative of significant differences between 
data sets.
Results
SM16 inhibits de novo Treg generation in vitro
To determine whether the mechanism by which SM16 
induces anti-tumor response involves the inhibition of de 
novo Treg generation, we first tested its capacity to block 
TGF-β-induced Treg generation from in  vitro CD3/
CD28-activated  CD4+CD25– and  CD4+CD25–GFP– T 
cells from BALB/c and FoxP3eGFP donors, respectively. 
As demonstrated in a representative example (Fig.  1), 
TGF-β induces Foxp3 expression in CD3/CD28 activated 
T cells (1A, 1D). Treatment with SM16 or TGF-β neu-
tralizing antibody (anti-TGF-β mAb) abrogated TGF-β 
-induced conversion to FoxP3 positive cells (1B, 1D). 
TCR activation in the absence of TGF-β did not stimulate 
FoxP3 expression (1A, 1C). Repeat independent experi-
ments confirmed SM16 blockade of TGF-β-induced Treg 
conversion (1E). Similarly, in  vitro stimulation of naive 
 CD4+CD25– cells from transgenic mice expressing a 
dominant negative form of TGF-β receptor type II [34] 
did not result in Treg conversion (data not shown).
SM16 enhances homeostatic proliferation and induces 
a population of  CD4+CD25–FoxP3+ cells in vivo
The blockade of TGF-β-induced Treg generation by 
SM16, was not unexpected as many studies have docu-
mented the key role of TGF-β signaling on induction and 
maintenance of Treg [2, 21–25]. However, this is the first 
report to demonstrate inhibition of FoxP3 expression 
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among  CD4+CD25−FoxP3− cells in vitro by a small mol-
ecule TGF-βRI signaling inhibitor. We next wanted to 
determine if SM16 could also prevent Treg generation 
in  vivo. We investigated the effectiveness of systemic 
blockade of TGF-βRI signaling on de novo Treg genera-
tion in vivo in adoptive transfer studies using RagKO mice 
reconstituted with  CD4+GFP– T cells from FoxP3eGFP 
donors. As shown in Fig. 2, all reconstituted mice main-
tained on SM16 diet demonstrated a statistically signifi-
cant increase in total  CD4+ cellularity in the lymph node 
and spleen. Calculation of the absolute cell numbers of 
different T cell populations revealed a statistically sig-
nificant increase in Treg cells  (CD4+CD25+FoxP3+), 
as well as activated  (CD4+CD25+FoxP3) and naive 
Fig. 1 FACS data of  CD4+CD25− or  CD4+CD25–FoxP3− T cells from spleen of BALB/c and FoxP3eGFP mice. Cells were treated in vitro for 72 h with 
CD3/CD28 antibodies as described in the “Methods” section. Plots show CD25-PE on the y-axis and FoxP3-APC or FoxP3eGFP on the x-axis. Quadrant 
statistics noted are percent of live  CD4+ gate. a–d Mean values of %  CD4+CD25+Foxp3+ from 5 independent experiments show SM16 effects on 
TGF-β-induced Treg conversion (e). Significance between control and experimental groups were determined by Student’s t-test (*, P < 0.05)
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 (CD4+CD25–FoxP3–) T cells in both LN and spleen 
(Table  1). Since the adoptive transfer studies suggested 
that SM16 might induce global T cell proliferation, we 
further tested its effect on endogenous T cell prolifera-
tion in lymphoreplete mice. SM16 treatment resulted 
in increased frequency of  CD4+CD25−FoxP3+ T cells 
from gated  CD4+ T cells in both spleen and lymph node 
(Fig.  3a).  CD4+CD25+FoxP3+ T cells were also signifi-
cantly increased in spleen cells, and trended higher in 
lymph node cells (Fig. 3b).
SM16 reduces suppressive activity of  CD4+CD25+FoxP3+ 
and CD4 + CD25−FoxP3+ T cells
Although our in  vivo data demonstrated that SM16 did 
not prevent de novo Treg generation, but instead induced 
global expansion of  CD4+ T cells, we further sought to 
determine whether SM16 treatment had an impact on 
the function (suppressive activity) of Treg. As shown 
in Fig.  4a,  CD4+CD25+FoxP3+ T cells enriched from 
spleen of mice on control diet were significantly more 
efficient at suppressing thymidine uptake by CD3-stim-
ulated responder cells compared to mice on SM16 diet. 
Similarly,  CD4+CD25−FoxP3+ T cells enriched from 
SM16-treated donors demonstrated reduced suppressive 
activity as compared to their counterparts on control diet 
(Fig. 4b).
SM16 expands  FoxP3+ cells in tumor bearing mice
We previously demonstrated that 0.45  g/kg-dose of 
SM16 dramatically reduces the growth of primary and 
metastatic 4T1 tumors [19]. To determine whether 
the beneficial anti-tumor effects of SM16 were associ-
ated with changes in the Treg compartment, we ana-
lyzed the frequency of FoxP3+ cells in the presence or 
absence of SM16 in a tumor prevention model in which 
mice receiving injection of 4TI cells into the mammary 
pad were immediately put on control or SM16 diet. As 
in our earlier study, we again showed this dose of SM16 
significantly inhibited tumor growth (Fig. 5). The inhibi-
tory effect of SM16 on primary tumor growth was asso-
ciated with a significant increase in  CD4+CD25–FoxP3+ 
in the spleen but not in the tumor draining lymph nodes 
or tumor (Fig.  6a). Notably, there was no increase in 
Fig. 2 Total  CD4+ T cell recovery from lymph node and spleen of 
RagKO mice reconstituted with  CD4+GFP− cells from FoxP3eGFP 
donors. The cells were isolated from recipients 21 days after cell 
transfer and treatment with SM16. Control mice were maintained 
on standard diet. Data presented are mean of 4 independent 
experiments. Significance between control and experimental groups 
were determined by Student’s t-test
Table 1 The absolute cell number of   CD4+ T cell subsets calculated based on  flow cytometry analysis of  lymph nodes 
and spleen of RagKO mice reconstituted with  CD4+GFP−T cells and maintained on control or SM16 diet for 21 days
Absolute numbers (AN) are presented as the mean trait value ± SEM. The % was determined based on average of ANs from 4 independent experiments
*p value ≤ 0.05, as compared to RagkO on control diet
# p value ≤ 0.05, as compared to RagkO on control diet
& p value ≤ 0.05, as compared to RagkO on control diet
a p value ≤ 0.05, as compared to RagkO on control diet
b p value ≤ 0.05, as compared to RagkO on control diet
c p value ≤ 0.05, as compared to RagkO on control diet
Absolute cell number per mouse  (105)
Lymph node Spleen
Treatment Control (%) SM16 (%) Control (%) SM16 (%)
Total cell recovery
 All  CD4+ 1.18 ± 0.5 13.5 ± 1.4 21.7 ± 0.05 88.8 ± 1.90
 CD4+  CD25+  Foxp3+ (Treg) 0.1 ± 0.06 (1.4) 0.4 ± 0.03* (3.6) 0.4 ± 0.2 (3.7) 2.5 ± 1.03a (3.8)
 CD4+  CD25+  Foxp3− (activated T cell) 0.08 ± 0.04 (8.3) 0.7 ± 0.04# (6.4) 1.6 ± 1.3 (3.9) 2.5 ± 0.7b (2.7)
 CD4+  CD25−  Foxp3− (other) 1.0 ± 0.5 (91.3) 12.4 ± 6.3& (90.0) 19.7 ± 0.01 (94.0) 83.8 ± 0.01c (93.5)
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 CD4+CD25+FoxP3+ T cells in all studied tissues in 
tumor-bearing (TBM) mice on SM16 diet (Fig. 6b).
SM16 attenuates the suppressive activity of Treg in mice 
bearing established tumor
SM16 treatment of tumor-bearing mice resulted 
in reduced suppressive activity of splenic 
 CD4+CD25+ cells. As shown in Fig.  7,  CD4+CD25+ 
T cells from spleen of TBM on control diet signifi-
cantly inhibited proliferation of CD3-stimulated 
 CD4+CD25− responder cells as compared to SM16-fed 
mice. In addition to assessing the ability of  CD4+CD25+ 
T cells to inhibit proliferation, we measured their 
effect on IFN-γ production by the  CD4+CD25− naive 
responders. Treg, responders and APC (irradiated 
CD90-depleted splenocytes) were plated at 1:1:1 ratio. 
As shown in Fig. 8,  CD4+CD25+ T cells isolated from 
spleen of TBM on control diet, significantly reduced 
IFN-γ production by responder T cells. In contrast, 
co-incubation of responder T cells with  CD4+CD25+ 
Fig. 3 Frequency of  CD25−FoxP3+ and  CD25+FoxP3+ (Treg) cells, respectively among  CD4+ cells isolated from lymph node and spleen. Naive 
FoxP3eGFP mice were maintained for 14 days on control or SM16 diet. Subsequently, mice were sacrificed, and lymph node and spleen were 
isolated to perform flow cytometry analysis. Frequency of  CD25−FoxP3+ (a) and  CD25+FoxP3+ Tregs (b) cells. Data presented are mean values from 
eight animals in 2 independent experiments. Significance between control and experimental groups were determined by Student’s t-test
Fig. 4 In vitro suppressive activity of  CD4+CD25+FoxP3+ (a) and  CD4+CD25−FoxP3+ (b) T cells isolated from naive or SM16 treated FoxP3eGFP 
mice.  CD4+CD25+FoxP3+ and  CD4+CD25−FoxP3+ cells from donor mice were obtained by FACS sorting. The activity of isolated cells having 
the ability to suppress naive T cell proliferation in an in vitro assay was tested by adding increasing numbers of  CD4+CD25+FoxP3+ or 
 CD4+CD25−FoxP3+ T cells to co-cultures of sorted  CD4+CD25− (responder cells) and APCs from naive mice in the presence of anti-CD3. After 48 h 
the plates were pulsed for 18 h with  [3H]-thymidine. Subsequently, the cells were harvested on glass fiber filters and assessed for uptake of the 
labeled thymidine by liquid scintillation (4 and 3 independent experiments respectively). Repeat assays of  CD4+CD25+Foxp3+ cells were performed 
using a single batch of naive responder mice. Similarly, repeat assays of  CD4+  CD25−Foxp3+ cells were performed using a separate batch of 
responder cells from naive mice
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T cells isolated from spleen of SM16-fed TBM partially 
restored IFN-γ production.
Discussion
CD4+CD25+FoxP3+ regulatory T cells are crucial to the 
maintenance of tolerance in normal individuals, and, so 
far gathered evidence indicates that presentation and 
progression of certain immunological disorders as well as 
the progression of cancer may be a function of Treg cell 
behavior [35]. Although, the factors regulating this cell 
population are still ill defined, it has been shown that 
TGF-β contributes directly to Treg differentiation and/or 
function [36]. Thus, TGF-β can be classified as a pro-tol-
erance agent, and, once present in the tumor microenvi-
ronment, it promotes immune tolerance to tumor cells by 
several mechanisms including expansion of the regula-
tory Treg compartment [12, 13]. This phenomenon has 
been recently implicated as one of the major factors con-
tributing to immune evasion by tumors [37]. Thus, there 
has been a strong interest in finding strategies for block-
ing TGF-β signaling to overcome peripheral tolerance in 
order to enhance antitumor immunity. TGF-β signals 
through a heterodimeric receptor complex formed by 
association of TGF-βRI and TGF-βRII subunits with 
ligand. However, only binding of TGF- β to the TGF-βRI 
subunit of the receptor complex activates the intracellu-
lar kinase domain, which leads to the phosphorylation 
and activation of the Smad protein family and subsequent 
regulation of TGF-β-dependent gene expression [38]. 
Up-regulation of FoxP3 expression and acquisition of the 
regulatory phenotype by peripheral T cells is directly 
linked to TGF-β-induced Smad signaling [15]. However, 
TGF-β signaling blockade initiated by preventing the 
binding of ligand to the receptor via the use of antibod-
ies, (antibodies neutralizing TGF-β peptide) or inhibitors 
of TGF-βRII activation has only been partially effective, 
and the major issue in reducing Treg effects is insufficient 
system saturation resulting in leakiness and incomplete 
inhibition of Smad signaling. For the above reason, the 
utilization of highly selective inhibitors of TGF-βR can 
guarantee a more robust inhibition of signaling and effec-
tively prevent changes in gene expression, including the 
up-regulation of FoxP3. In the present work, we have 
Fig. 5 Primary tumor size in SM16-fed and control mice. Data 
represent average tumor size from all animals in 3 independent 
experiments. Significance between control and experimental groups 
was determined by Student’s t-test
Fig. 6 Frequency of  CD4+CD25−FoxP3+ (a) and  CD4+CD25+FoxP3+ T cells (b) in lymph node, spleen and TIL. Cells were stained with anti-mouse 
CD4 and anti-mouse CD25 and after permeabilization, cells were stained additionally with FoxP3. Data represent average of 3 independent 
experiments. Significance between control and experimental groups were determined by Student’s t-test
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identified SM16, a small molecule TGF-β signaling inhib-
itor, which binds the ATP pocket of TGF-βR1, and works 
as an anti-tolerance regulator of the Treg compartment. 
As shown herein, SM16 directly blocks the in vitro prolif-
erative expansion of  CD4+CD25+FoxP3+ Treg cells 
induced by TGF-β from BALB/c splenic  CD4+CD25− 
precursors (Fig.  1a, b), and from FoxP3eGFP splenic 
 CD4+CD25−FoxP3− precursors (Fig.  1c, d). Although 
SM16 inhibited the Treg inductive effect of TGF-β across 
multiple in  vitro experiments (Fig.  1e), it did not block 
the expansion of Treg in vivo in transfer experiments of 
 CD4+/GFP− (FoxP3eGFP donors) donor cells transferred 
into lymphodepleted RagKO mice, or into lymphoreplete 
normal recipient mice. Previous reports have docu-
mented the in vivo effects of TGF-β to inhibit IL-2 pro-
duction and T cell proliferation and differentiation [8, 
39–41]. Thus, it was not unexpected that in vivo adminis-
tration of SM16 would promote a broad homeostatic 
expansion of total cellularity in both the lymph nodes 
and spleens of recipient mice (Fig. 2); and, which resulted 
in statistically significant increases in absolute numbers 
of Treg  (CD4+CD25+FoxP3+), activated T cells 
 (CD4+CD25+FoxP3−) and naive  (CD4+CD25−FoxP3−) T 
cells due to the blunting of autologous in  vivo TGF-β 
effects. Attenuated TGF-β function may thus have 
resulted in concomitant increased systemic IL-2 produc-
tion, and, simultaneously, abrogated Treg function, if not 
their frequency, in vivo (Table 1). Notably, in vivo SM16 
administration stimulated the significant expansion of 
not only Tregs, but also a second “Treg-like” subpopula-
tion  (CD4+CD25−FoxP3+) in splenocytes and lymph 
node cells of lymphoreplete mice (Fig. 3a, b). Our studies 
therefore indicate that SM16 is not sufficient to inhibit 
the induction of the regulatory phenotype in activated 
cells and prevent expansion of Treg compartment in vivo. 
However, although SM16 did not reduce the in vivo fre-
quency and absolute numbers of Treg cells, Treg from 
SM16 treated FoxP3eGFP animals showed significantly 
lower levels of suppression of CD3 stimulated T cell pro-
liferation compared to Treg from naive untreated con-
trols in a standard Treg functional assay (Fig.  4a). 
Similarly, the “Treg-like”  (CD4+CD25−FoxP3+) subpopu-
lation also showed significantly lower levels of suppres-
sion in a Treg functional assay (Fig.  4b). The anergy of 
Treg subpopulations in SM16 treated normal naive mice 
was also reflected in Treg subpopulations examined in 
SM16 treated TBM. Thus, although SM16 administration 
resulted in significantly inhibited tumor growth (Fig.  5) 
and concomitant increase in the  CD4+CD25−FoxP3+ 
Treg-like subpopulation (Fig. 6a), it did not significantly 
increase the  CD4+CD25+FoxP3+ Treg subpopulation in 
the spleen, lymph nodes or tumor microenvironment of 
TBM (Fig. 6b). Moreover,  CD4+CD25+FoxP3+ Treg from 
TMB mice fed SM16 were significantly less suppressive 
in the standard Treg suppression assay than Treg from 
spleens of untreated TMB control mice (Fig. 7). Similarly, 
Fig. 7 Treg having the ability to suppress the proliferation of naive 
T cells isolated from spleen of TBM BALB/c mice, fed control or SM16 
diet for 19 days.  CD4+CD25+ cells from donor mice were obtained 
by FACS sorting. The activity of isolated suppressor cells was tested 
by adding increasing ratios of  CD4+CD25+ T cells to co-cultures of 
sorted  CD4+CD25− (responder cells) and APCs from naive mice in 
the presence of anti-CD3. After 48 h the plates were pulsed for 18 h 
with  [3H]-thymidine. Subsequently, the cells were harvested on glass 
fiber filters and assessed for uptake of the labeled thymidine by liquid 
scintillation (3 independent experiments)
Fig. 8 Effect of  CD4+CD25+ T cells from TBM on IFN-γ production. 
 CD4+CD25+ T cells from TBM either on control or SM16 diet were 
co-cultured with  CD4+CD25− responder T cells from naive donors 
(ratio: 1:1) and stimulated with irradiated APC and soluble anti-CD3 
mAb. After 72 h supernatants were harvested from the co-cultures 
and were analyzed for IFN-γ concentrations. The amounts of IFN-γ 
production were evaluated in triplicate using OptEIA ELISA kit 
(Pharmingen). The presented value of IFN-γ production corresponds 
to 5 × 104 cells. Bars represent mean values ± SEM (n = 3 from a single 
experiment). Significance between control and experimental groups 
were determined by Student’s t-test
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Treg from SM16 treated TBM were significantly less 
effective at suppressing IFN-γ secretion by CD3 activated 
T cells in vitro when compared to Treg from non-treated 
TBM control mice (Fig.  8). These findings may provide 
further explanation for the enhanced IFN-γ production 
and antitumor CTL activity in splenocytes from SM16-
treated mice that we observed in our earlier studies [19, 
26]. The blockade of TGF-β signaling has been shown to 
restore the frequency, persistence and cytotoxic activity 
among  CD8+ T cells in various established tumor mod-
els, and may work in part by blocking Treg expansion and 
activation [42, 43]. Thus, our data suggest that while sys-
temic blockade of TGF-βRI signaling may diminish the 
suppressive potential of Treg cells, it does so without 
substantially reducing their frequency or absolute num-
bers in SM16 treated mice. Unexpectedly, our study also 
revealed the expansion of a “Treg-like”  CD4+ subpopula-
tion which lacked CD25 expression but retained FoxP3 in 
splenocytes from SM16 treated normal control and 
TBM. Although these  CD4+CD25−FoxP3+ cells showed 
diminished suppressor function comparable to Tregs 
 (CD4+CD25+FoxP3+) in normal controls, we did not 
study them in SM16 treated TBM. However, Bonelli and 
co-workers have described significant increases in a 
 CD4+CD25−FoxP3+ subpopulation which correlates 
with progression of disease in SLE patients [44, 45]. Their 
detailed phenotype analysis indicated this subpopulation 
more closely resembled regulatory T cells rather than 
activated T cells; and although they could suppress T cell 
proliferation in  vitro they could not inhibit IFN-γ pro-
duction [45]. The report by Bonelli was preceded by sev-
eral earlier studies, which collectively indicated the 
importance of CD25 as a possible activation marker 
within Tregs [46–48]. Moreover, loss of CD25 expression 
is also thought to be primarily responsible for age-
dependent functional decline of Treg cells [49, 50]. The 
underlying reasons for the observed change in distribu-
tion of CD25 expression need further investigation and 
are still unknown. The SM16 induced expansion of the 
 CD4+CD25−FoxP3+subpopulation, which also displayed 
a diminished capacity to suppress T cell proliferation, is 
of special interest. Previous reports have suggested 
TGF-β alone was sufficient in vitro and in vivo to induce 
first FoxP3 expression, and subsequently  CD25+ expres-
sion on peripheral TCR activated Treg precursors [14, 
15]. However, more recent studies suggest that IL-2 is 
also required for TGF-β to trigger naive  CD4+CD25− 
cells to become  CD25+ and express FoxP3 and develop 
into fully functional Treg [38, 51]. Thus, it is tempting to 
speculate that the  CD4+CD25−FoxP3+ subpopulation 
may represent an expanding precursor pool of Treg 
which have been arrested in their differentiation by the 
SM16 induced dysregulation of the previously described 
IL-2/TGF-β signaling interaction [52] which may play a 
role in inducing fully functional Tregs. This conclusion is 
further supported by the observation that majority of 
these cells reside within the proliferating  Ki67+ compart-
ment (unpublished data). This hypothesis is also 
strengthened by many reports that highly enriched poly-
clonal  CD4+CD25− T cells can convert to  CD4+CD25+ 
T cells in vivo upon homeostatic proliferation in different 
lymphopenic models [53, 54]. These newly generated 
 CD4+CD25+ T cells were shown to be phenotypically 
and functionally the same as naturally occurring Tregs.
Conclusions
The present study demonstrated that systemic blockade 
of TGF-βR signaling using SM16 does not change in vivo 
Treg frequency, and results in the global expansion of 
absolute numbers of T cells, including Treg. Notably, 
the blockade of normal TGF-β activation is reflected pri-
marily in reduced suppressive activity and the inability 
of Treg to inhibit IFN-γ production from effectors cells. 
Furthermore, tissue-selective expansion of a subpopula-
tion of “Treg-like” cells  (CD4+CD25−FoxP3+) suggests 
that SM16 induces a population of cells which might 
resemble dysfunctional Treg cells found in both mice and 
humans suffering from autoimmune disorder due to the 
loss of Treg functionality. Herein, we hypothesize that 
these cells may represent a pool of Treg precursors which 
are arrested in their normal differentiation pathway and 
are not fully functional. Better understanding of how 
these cells, which also occur in autoimmune individuals, 
may support antitumor immune response in tumor bear-
ing mice and may lead to novel therapeutic approaches 
to combat immune evasion by tumors and other diseases.
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